A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort Turbuhaler+ Bricasol pMDI Compared With Pulmicort Turbuhaler+Bricasol pMDI in Chinese Patients With COPD

Trial Profile

A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort Turbuhaler+ Bricasol pMDI Compared With Pulmicort Turbuhaler+Bricasol pMDI in Chinese Patients With COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Feb 2008 Status change from in progress to completed, as reported by clinicaltrials.gov.
    • 11 Jan 2008 The expected completion date for this trial is now 1 Jan 2008.
    • 26 Jul 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top